Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Eknath A, Deo"'
Autor:
Paula J. Bernard, Renata D'Alpino Peixoto, Eknath A. Deo, Steven S. Evans, Robert A. Nagourney, Adam J. Nagourney, Federico R. Francisco
Publikováno v:
Journal of Clinical Oncology. 36:e14568-e14568
e14568Background: The biguanide metformin is a widely used oral hypoglycemic. One mode of action is the inhibition of mitochondrial complex I and activation of AMP kinase with down-regulation of mT...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50e83cfba40c7c54ff3108c0b73b543c
https://doi.org/10.1200/jco.2018.36.15_suppl.e14568
https://doi.org/10.1200/jco.2018.36.15_suppl.e14568
Autor:
Federico R. Francisco, Robert A. Nagourney, Nilesh Vora, Alexander J. Nagourney, Milan Rohit Sheth, Eknath A. Deo, Paula J. Bernard, Steven Evans
Publikováno v:
Cancer Research. 77:4684-4684
The transcription factor MYC is associated with the regulation of over 15% of human gene expression. Deregulation of MYC is found in up to 70% of human cancers. As MYC is responsible for the reprogramming of cell metabolism, growth and survival, it i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::129951a9504ece9c43af65ff8465b876
https://doi.org/10.1158/1538-7445.am2017-4684
https://doi.org/10.1158/1538-7445.am2017-4684
Autor:
Milan Rohit Sheth, Robert A. Nagourney, Steven S. Evans, Federico R. Francisco, Paula J. Bernard, Nilesh Vora, Eknath A. Deo, Ryan Wexler
Publikováno v:
Journal of Clinical Oncology. 34:e14114-e14114
e14114Background: Up to 70% of human cancers overexpress MYC oncogenes, many via mutation, amplification or translocation, yet MYC has remained a challenging target for therapeutic intervention. MY...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::760921b1adf675e0a99f4829a3fcb680
https://doi.org/10.1200/jco.2016.34.15_suppl.e14114
https://doi.org/10.1200/jco.2016.34.15_suppl.e14114
Autor:
Robert A, Nagourney, Jonathan B, Blitzer, Robert L, Shuman, Thomas J, Asciuto, Eknath A, Deo, Marylyn, Paulsen, Robert L, Newcomb, Steve S, Evans
Publikováno v:
Anticancer research. 32(10)
To assess the impact of drug selection upon the treatment of advanced and metastatic non-small cell lung cancer (NSCLC), we applied a functional platform that measures drug-induced cell death in human tumor primary-culture micro-spheroids isolated fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::07a41762cad83315fceb7a82b9a31632
https://pubmed.ncbi.nlm.nih.gov/23060572
https://pubmed.ncbi.nlm.nih.gov/23060572
Autor:
Eknath A. Deo, Robert A. Nagourney, Paula J. Bernard, Steven S. Evans, Milan Rohit Sheth, Federico R. Francisco, Nilesh Vora
Publikováno v:
Journal of Clinical Oncology. 32:e13504-e13504
e13504 Background: The cyclin dependent kinases (CDK) are a family of enzymes that mediate cell cycle progression. CDK dysregulation is a common event in human carcinogenesis, making CDK inhibition...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17c8dd7332cd5b3b52e934d77c591bd8
https://doi.org/10.1200/jco.2014.32.15_suppl.e13504
https://doi.org/10.1200/jco.2014.32.15_suppl.e13504
Autor:
R. A. Nagourney, D. Mc Connell, Steven S. Evans, Eknath A. Deo, T. Asciuto, M. Paulsen, J. B. Blitzer, R. Nandan, R. Shuman
Publikováno v:
Journal of Clinical Oncology. 28:7617-7617
7617 Background: Personalized chemotherapy is an important advance for NSCLC pts. While genomic platforms have identified prognostic and predictive factors e.g., ERCC1 and RRM1/2, proteomic platfor...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::282db0962ad4fbd782f93a7fd5ddb46e
https://doi.org/10.1200/jco.2010.28.15_suppl.7617
https://doi.org/10.1200/jco.2010.28.15_suppl.7617
Autor:
Steven S. Evans, R. Nandan, R. A. Nagourney, T. Asciuto, M. Paulsen, D. Mc Connell, J. B. Blitzer, Eknath A. Deo, R. Schuman
Publikováno v:
Journal of Clinical Oncology. 27:e19079-e19079
e19079 Background: The introduction of new classes of agents has improved survival in NSCLC yet the accurate selection of candidates for these often costly & toxic drugs remains a challenge. Genomic platforms have identified several prognostic & pred
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2f41b3c500cfc8c8a88f4e018c23c8b
https://doi.org/10.1200/jco.2009.27.15_suppl.e19079
https://doi.org/10.1200/jco.2009.27.15_suppl.e19079